Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novamind Inc. NVMDF

Healthcare Biotechnology
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence... see more

Recent & Breaking News (OTCQB:NVMDF)

Novamind (CSE: NM) to present at Benzinga Cannabis Capital Conference

Trevor Abes  February 24, 2021

Novamind to Present at Benzinga Conference

Accesswire February 23, 2021

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

Accesswire February 22, 2021

Novamind Announces Symbol Change on OTC Market To "NVMDF"

Accesswire February 19, 2021

Canadian Securities Exchange Reports Record Trading Volume and Capital Raised for January 2021

Newsfile February 16, 2021

Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial

Accesswire February 11, 2021

Novamind to Present at Canaccord Genuity Conference: "New Paradigms & Treatment Approaches in Mental Health"

Accesswire January 29, 2021

Novamind Reaches Major Milestones for Ketamine and Spravato(TM) Treatments

Accesswire January 28, 2021

Novamind Announces Marketing Services Agreements

Accesswire January 26, 2021

Novamind to Present at Inaugural KCSA Psychedelics Investor Conference

Accesswire January 25, 2021

Former LifeLabs COO Joins Novamind Leadership Team

Accesswire January 19, 2021

Novamind Expands Psychedelic Medicine Access in Utah

Accesswire January 13, 2021

KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021

PR Newswire January 11, 2021

Novamind Appoints Chuck Rifici to its Board of Directors

Accesswire January 8, 2021

Novamind to Commence Trading (CSE:NM) on January 5th, 2021

Canadian Press, with file by Stockhouse January 5, 2021

Novamind to Present at the SNN Network Canada Virtual Event on January 7, 2021

Canadian Press, with file by Stockhouse December 31, 2020

Novamind Completes Reverse Takeover Transaction

Canadian Press, with file by Stockhouse December 24, 2020

Novamind Receives CSE Conditional Listing Approval Under the Ticker “NM”

Canadian Press, with file by Stockhouse December 22, 2020

Novamind to Participate in MAPS Canada Webinar on Eating Disorders and PTSD

Canadian Press, with file by Stockhouse November 24, 2020

Novamind Closes Oversubscribed CAD$10 Million Private Placement

Canadian Press, with file by Stockhouse November 23, 2020